Vista Exclusive Content
J&J Accelerates Quarterly Profits
Recently, Johnson & Johnson (JNJ) announced that their Q1 earnings which exceeded market expectations. The company highlighted how their drug Stelara, used for the treatment of psoriasis and Crohn’s disease, enjoyed a double-digit increase of about 32% bringing it to $1.41 billion & now is
“Earnings, Earnings, Earnings” – Vista Partners Daily Market Recap 4/16/2019
Stocks ended the day up today, with all three of the major indices notching gains. The Nasdaq finished the session with an increase of 0.30% (24.21 points). Meanwhile, the S&P 500 climbed 0.05% (1.48 points) to end the session. The Dow closed out the day
FDA Approves Johnson & Johnson’s Advanced Bladder Cancer Drug
According to The American Cancer Society’s website estimates for bladder cancer in the United States for 2019 are about 80,470 new cases of bladder cancer (about 61,700 in men and 18,770 in women and about 17,670 deaths from bladder cancer (about 12,870 in men and 4,800
Company News Around The Web
19 May 2019 | 8:18 am
Modi’s jobs deficit - J&J’s largest India...
PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be ...
19 May 2019 | 8:08 am
Modi’s jobs deficit: J&J’s largest India plant...
PENJERLA/NEW DELHI, India May 19 (Reuters) - It was supposed...
18 May 2019 | 7:18 pm
Bulls And Bears Of The Week: Apple,...
Benzinga has examined prospects for many investor favorite s...
18 May 2019 | 4:19 pm
6 Things Johnson & Johnson Wants You...
Here's what management wants investors to know about th...
17 May 2019 | 9:30 pm
Why This Biotech Stock Looks Prime For...
Dow Jones component Johnson & Johnson could buy out biot...
17 May 2019 | 9:03 pm
Exclusive: FBI targets Johnson & Johnson, Siemens,...
The U.S. FBI is investigating corporate giants Johnson &...
|Day Low - High||-|
|Year Low - High||-|